Respiratory Syncytial Virus Vaccine Development
Respiratory Syncytial Virus Vaccine Development
复制标题
DOI：
10.1016/j.cll.2009.07.004
复制
发表时间：
2009-12-01
影响因子：
1.7
通讯作者：
Murata, Yoshihiko
中科院分区：
文献类型：
--
作者：
Murata, Yoshihiko
呼吸道合胞病毒（RSV）是呼吸道疾病的一个临床重要原因，特别是在高危婴儿和免疫功能低下的老年人中。尽管存在疾病负担，但尚无获得许可的预防性RSV疫苗。开发RSV疫苗的最初努力涉及福尔马林灭活的病毒制剂，其在RSV初治儿童的临床试验中意外地引起疫苗增强的疾病。在过去的40年中，使用各种实验方法，包括减毒活毒株和基于载体和基于病毒蛋白亚基/DNA的候选物，在RSV疫苗开发方面取得了谨慎和故意的进展。这些方法的科学原理，临床前测试和临床发展进行了审查。
Respiratory syncytial virus (RSV) is a clinically significant cause of respiratory tract disease, especially among high-risk infants and immunocompromised and elderly adults. Despite the burden of disease, there is no licensed prophylactic RSV vaccine. The initial efforts to develop an RSV vaccine involved formalin-inactivated virus preparations that unexpectedly caused vaccine-enhanced disease in clinical trials in RSV-naive children. Over the last 40 years, cautious and deliberate progress has been made toward RSV vaccine development using various experimental approaches, including live attenuated strains and vector-based and viral protein subunit/DNA-based candidates. The scientific rationale, preclinical testing, and clinical development of each of these approaches are reviewed.